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Abstract
Background: Transmission of hepatitis B virus (HBV) from HBV-positive mothers to their infants is common and
usually occurs when the mother is hepatitis B e antigen (HBeAg) positive and/or has a high HBV DNA load. In this
study, we determined the prevalence of hepatitis B surface antigen (HBsAg) and HBeAg among pregnant women
with known HIV status.
Findings: A total of 650 pregnant women with a mean age of 26.2 years including 301 HIV-positives and 349 HIV-
negatives were screened for HBsAg (Monolisa AgHBs Plus Biorad, France). Among the HBsAg-positives, HBeAg and
anti-HBe were tested (Monolisa Ag HBe Plus Biorad, France). Overall, 51 (7.85%) were positive for HBsAg. The
prevalence of HBsAg was not statistically different between HIV-positive and HIV-negative pregnant women [28/
301 (9.3%) vs 23/349 (6.59%); p = 0.2]. None of the 45 HBsAg-positive samples was reactive for HBeAg.
Conclusions: Our study indicates a high prevalence of HBsAg with very low proportion of HBeAg in Cameroonian
pregnant women. Since perinatal transmission of HBV is mostly effective when the mother is also HBeAg-positive,
our data could suggest that perinatal transmissions play a minor role in HBV prevalence in Cameroon. In line with
previous African studies, these findings further suggests that horizontal transmission could be the most common
mechanism of HBV infections in Cameroon.
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Introduction
Perinatal transmission of Hepatitis B virus (HBV) from
infected mothers to their children is suspected to repre-
sent a major mode of disease transmission in high-pre-
valence areas [1]. HBV infection can be passed from
infected mothers to their infants during pregnancy, at
the time of birth, or after birth with most transmissions
occurring during birth or in the perinatal period [2].
The risk of vertical transmission and resulting chronic
infection from a chronic carrier mother (i.e. hepatitis B
surface antigen (HBsAg) positive) to her infant is
approximately 90% in hepatitis B “e” antigen (HBeAg)
positive pregnant women with high HBV DNA titres
[3-6].
The introduction of HBV testing in all pregnant
women combined with immunoglobulin prophylaxis
and/or hepatitis B vaccination immediately after delivery
in all children born to HBsAg positive mothers have
been reported to be useful strategies to reduce the pre-
valence of hepatitis B virus infection [7]. These actions
would have the greatest impact in reducing the number
of new hepatitis B carriers since perinatal transmission
plays an important role in the maintenance of the reser-
voir of chronic HBV infections in areas of high preva-
lence of HBsAg ( ≥ 8%) like Cameroon.
Due to the shared modes of transmission, co-infec-
tions with HBV and HIV are common. The importance
of implementing appropriate prophylactic care and
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follow-up of pregnant women infected with HBV is fun-
damental. Furthermore it is equally important to identify
the HIV/HBV co-infected pregnant women since
infected pregnant women are put on HIV prophylaxis to
prevent mother-to-child transmission (MTCT) of HIV
without information on their HBV status.
The aim of this study therefore was to determine the
prevalence of hepatitis B surface antigen (HBsAg)
among pregnant women with known HIV status in
Yaounde, Cameroon.
Study design and laboratory analyses
This study included pregnant women who participated
in a Public Health Pilot Program (PHPP) for the Preven-
tion of mother-to-child transmission of HIV-1 [8] and
HCV [9] in Yaounde, Cameroon. Patients and Methods
have been described elsewhere [8,9]. Briefly, between
January 2000 and April 2003 these women were attend-
ing antenatal care at the mother and child center of the
“Fondation Chantal Biya” (FCB) in Yaounde. These stu-
dies were approved by the National Ethics Committee
and local health authorities in Cameroon and they also
received the consent of the participating pregnant
women. The women were screened for HIV as reported
elsewhere [8]. In this study therefore, we consecutively
selected 650 samples consisting of 301 HIV-positive and
349 HIV-negative samples from pregnant women. The
HIV positive samples were selected within the period
running from January 2000 to April 2003 while the HIV
negative samples were selected from January to July
2000. The two groups were tested for HBsAg (Monolisa
AgHBs Plus Biorad, France). This is a one step enzyme
immunoassay technique of the ‘sandwich’ type. HBsAg
positive samples were further tested for the presence of
HBeAg and hepatitis B ‘e’ antibodies (anti HBe) respec-
tively (Monolisa HBe Plus Biorad, France). The detec-
tion of HBeAg is based on a 2-step ‘sandwich’ enzyme
immunoassay. For the detection of anti HBe, the same
solid phase as for HBeAg was used. The test is based on
competition between the immobilised antibodies present
in the sample, towards a limited quantity of HBeAg
used as a neutralising reagent (Monolisa HBe Plus
Biorad, France).
Results
The mean age (n = 550) in this study was 26.17 years
(95% CI 25.7-26.6) with comparable values between the
two groups: mean of 26.66 years (95% CI: 26.02-27.29
years) for HIV infected (n = 250) versus mean of 25.76
years (95% CI:25.12-26.40 years) for HIV uninfected (n
= 300) women. A total of 51 (7.85%) out of the 650
pregnant women were found positive for HBsAg.
Among these, 28/301 (9.3%) HIV-positive pregnant
women and 23/349 (6.59%) HIV-negative pregnant
women were HBsAg positive. HBV prevalence in these
two groups was not statistically different (p = 0.2).
Because of sample exhaustion, 45 out of 51 HBsAg-posi-
tive samples were tested for both HBeAg and anti HBe
respectively. None of the 45 samples tested for HBeAg
was positive.
Discussions
The results of this study indicate a high prevalence of
HBV infection among pregnant women in Cameroon.
To the best of our knowledge, this is the first study car-
ried out among pregnant women in an urban setting in
Cameroon. Earlier studies had reported an HBsAg pre-
valence of 5.4% among pregnant women in a rural set-
ting in Cameroon [10]. In a previous study in a general
population of Cameroon, about 9.6% of the 272 indivi-
duals tested were HBsAg-positive [11]. Another study
on city school children reported a high HBsAg preva-
lence of 19.9% among the 702 school children tested
[12]. This high prevalence in children could be due in
part to mother-to-child transmission and also could be
due to horizontal transmissions between school children
[13]. The high prevalence of HBsAg observed in this
study among pregnant women could be an indication
that pregnant women serve as a very important reservoir
to fuel the HBV epidemic in the general population.
However, previous studies indicate that in areas of high
HBV prevalence (i.e. ≥ 8%) like Cameroon, transmission
is said to be predominantly during childhood [14,15].
In our survey, HBsAg positivity rate was similar in
HIV-positive (9%) and negative pregnant women (7%).
Similar results have been obtained in Côte d’Ivoire [16]
a sub-Saharan African country just like Cameroon. This
high prevalence among HIV-positive and HIV-negative
pregnant women suggests that HBsAg screening should
be included as part of prenatal testing in Cameroon.
The role of sexual transmission could also be postulated
in this population of pregnant women in conformity to
what has been previously reported in Tanzania [17].
Hepatitis B ‘e’ status and viral load are factors asso-
ciated with the frequency of vertical transmission.
Despite the fact that similar and high prevalence of
HBsAg was observed in this study, no HBeAg reactive
sample was detected in this study population. HBeAg
reactive women are known to have a high viral load and
to transmit HBV to their children. The rate of materno-
fetal infection in East Asia, particularly China, was esti-
mated to be about 88% [18], compared with 8% or less
observed in the studies conducted in sub-Saharan Africa
[19-22]. This difference was largely attributed to the nat-
ural history of HBV infection in South-East Asia where
infected individuals carry HBeAg and high viral load in
age groups that include most women of gestational age
[23,24]. Conversely, in sub-Saharan Africa,
Kfutwah et al. Virology Journal 2012, 9:62
http://www.virologyj.com/content/9/1/62
Page 2 of 4
seroconversion to anti-HBe occurs before age 15 or 16,
with the consequence that most women of gestational
age carry anti-HBe [25]. Since perinatal transmission of
HBV is mostly effective when the mother is HBeAg-
positive, this form of transmission could play a negligi-
ble role in HBV transmission in Cameroon. Despite the
fact that this study did not test for mother-to-child
transmission of HBV we could conjecture that horizon-
tal transmissions could be the most common mechan-
ism of HBV infection in Cameroon, as reported in some
sub-Saharan African countries [20-22]. Before the inte-
gration of HBsAg screening into the routine package of
biological analyses carried out during pregnancy, we
presuppose that our results are in line and could be
considered as a justification of the current immunization
program. The present Cameroon vaccination program
against HBV consists of vaccination of all newborn at 6
weeks, efforts should therefore be directed at making
available these vaccines to all children in Cameroon
from 6 weeks old.
We are considering a follow-up of these findings on a
larger scale where more pregnant women would be
screened with the principal aim of determining the real
proportion of HBeAg positive pregnant women and the
ensuing mother to child transmission rates of HBV in
Cameroon.
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